Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.7), the stock would be worth ₹479.71 (12% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2 | ₹543.7 |
0%
|
| 3-Year Average | 1.7 | ₹479.71 |
-12%
|
| 5-Year Average | 1.7 | ₹479.71 |
-12%
|
| Industry Average | 6.3 | ₹1 754.41 |
+223%
|
| Country Average | 2.6 | ₹727.34 |
+34%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
₹75.8B
|
/ |
Jan 2026
₹42.6B
|
= |
|
|
₹75.8B
|
/ |
Mar 2026
₹44.9B
|
= |
|
|
₹75.8B
|
/ |
Mar 2027
₹50.2B
|
= |
|
|
₹75.8B
|
/ |
Mar 2028
₹57.9B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
A
|
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
|
83.2B INR | 2 | 26.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 327.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 3.9 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 5.1 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 18.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 7.1 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 5 | -119.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 9.6 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 1.7 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 6.5 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.6 |
| 70th Percentile | 4.6 |
| Max | 56 363.4 |
Other Multiples
Akums Drugs and Pharmaceuticals Ltd
Glance View
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution. The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.